Hot Selling Pharmaceutical Raw Material Powder 99% Clobetasol Propionate 25122-46-7

Home » Products » Pharmaceutical Intermediate » Hot Selling Pharmaceutical Raw Material Powder 99% Clobetasol Propionate 25122-46-7

Product Category

Contact Us

Tel: +86-571-85081802
Phone: +86-13655719091
E-mail: info@multin.cn
Add: Room 321,lingjun Mansion South,the 10th Chaowang Road,xiacheng District,hangzhou City,zhejiang Province China

(+86)-136-5571-9091

Hot Selling Pharmaceutical Raw Material Powder 99% Clobetasol Propionate 25122-46-7

Hot Selling Pharmaceutical Raw Material Powder 99% Clobetasol Propionate 25122-46-7

Hot Selling Pharmaceutical Raw Material Powder 99% Clobetasol Propionate 25122-46-7, find complete details about Hot Selling Pharmaceutical Raw Material Powder 99% Clobetasol Propionate 25122-46-7, Clobetasol Propionate, Clobetasol Propionate powder, Clobetasol Propionate price - Multinpharma

Model:
25122-46-7
Brand:
MT
Code:
25122-46-7
CAS.NO:
25122-46-7

Availability:



Inquire Add to Basket

Product Description

tianeptine 2

Product Name	Clobetasol Propionate powder
Appearance	White lyophilized powder
Assay	99%min
Test	HPLC
Certificate	ISO 9001
CAS	25122-46-7
MF	C25H32ClFO5
Storage Temperature	Cool Dry Place

Application:

Adrenocorticotropic hormone drugs, anti-inflammatory, anti-allergic and anti-drug more effective than prednisone, and promoting the removal of potassium sodium retention is very light, intramuscular or intravenous pituitary - adrenal strong inhibition:

1. Anti-inflammatory effects: The product can reduce and prevent tissue response to inflammation, thereby reducing inflammation performance. Hormone suppression of inflammatory cells, including leukocytes and macrophages accumulation in sites of inflammation and inhibition of phagocytosis, lysosomal enzyme release and synthesis and release of inflammatory chemical mediators. Can reduce and prevent tissue response to inflammation, thereby reducing inflammation performance.

2. Immunosuppressive effect: preventing or inhibiting cell-mediated immune response, delayed hypersensitivity reactions, reducing T lymphocytes, monocytes, eosinophils, reducing immunoglobulin binding to cell surface receptors and inhibition of the synthesis and release of interleukin, thus reducing the T lymphocyte transformation of lymphoblastoid cells, and reduce the extension of the primary immune response. Can reduce immune complexes through the basement membrane, and can reduce the concentration of ingredients complement and immunoglobulins.